NasdaqGS - Nasdaq Real Time Price USD

Bicycle Therapeutics plc (BCYC)

8.40
-0.11
(-1.35%)
As of 11:46:59 AM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
25,722
35,275
26,976
14,463
11,697
Operating Expense
273,093
244,428
216,328
131,116
77,315
Operating Income
-247,371
-209,153
-189,352
-116,653
-65,618
Net Non Operating Interest Income Expense
36,114
32,554
10,739
2,412
-2,864
Other Income Expense
2,533
2,803
-594
-555
358
Pretax Income
-208,724
-173,796
-179,207
-114,241
-68,482
Tax Provision
-5,502
-4,765
1,457
-1,524
-1,663
Net Income Common Stockholders
-203,222
-169,031
-180,664
-112,717
-66,819
Diluted NI Available to Com Stockholders
-203,222
-169,031
-180,664
-112,717
-66,819
Basic EPS
-3.16
-2.90
-5.08
-3.80
-2.67
Diluted EPS
-3.16
-2.90
-5.08
-3.80
-2.67
Basic Average Shares
64,866.81
58,207.59
35,592.36
29,660.66
25,061.73
Diluted Average Shares
64,866.81
58,207.59
35,592.36
29,660.66
25,061.73
Total Operating Income as Reported
-248,360
-209,872
-189,946
-116,653
-65,618
Total Expenses
273,093
244,428
216,328
131,116
77,315
Net Income from Continuing & Discontinued Operation
-203,222
-169,031
-180,664
-112,717
-66,819
Normalized Income
-201,330.22
-167,403.17
-180,182.86
-112,717
-66,819
Interest Income
37,074
34,284
14,002
5,756
120
Interest Expense
960
1,730
3,263
3,344
2,984
Net Interest Income
36,114
32,554
10,739
2,412
-2,864
EBIT
-207,764
-172,066
-175,944
-110,897
-65,498
EBITDA
-200,614
-164,892
-169,398
-107,208
-64,089
Reconciled Depreciation
7,150
7,174
6,546
3,689
1,409
Net Income from Continuing Operation Net Minority Interest
-203,222
-169,031
-180,664
-112,717
-66,819
Total Unusual Items Excluding Goodwill
-1,943
-1,673
-594
0
358
Total Unusual Items
-1,943
-1,673
-594
0
358
Normalized EBITDA
-198,671
-163,219
-168,804
-107,208
-64,089
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-51.22
-45.17
-112.86
0
0
12/31/2021 - 5/23/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ACET Adicet Bio, Inc.
0.7087
-5.43%
 
IDYA IDEAYA Biosciences, Inc.
19.53
-0.51%
 
KYMR Kymera Therapeutics, Inc.
30.99
-1.45%
 
KURA Kura Oncology, Inc.
6.41
+0.39%
 
RCUS Arcus Biosciences, Inc.
8.66
-2.37%
 
MBX MBX Biosciences, Inc.
11.78
-4.74%
 
SNDX Syndax Pharmaceuticals, Inc.
11.03
+4.31%
 
REPL Replimune Group, Inc.
9.19
0.00%
 
BCAX Bicara Therapeutics Inc.
15.47
+2.86%
 
TCRX TScan Therapeutics, Inc.
1.2050
-0.41%